209 results on '"Eisenberger U"'
Search Results
2. Lupusnephritis
3. Wartelistenmanagement vor Nierentransplantation
4. WCN23-0403 AN OPEN-LABEL, NON-RANDOMIZED EXTENSION STUDY TO EVALUATE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF LNP023 IN SUBJECTS WITH C3 GLOMERULOPATHY: INTERIM ANALYSIS OF PHASE 2 STUDY
5. Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study
6. Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study
7. Meta-Analyses Qualify Metzincins and Related Genes as Acute Rejection Markers in Renal Transplant Patients
8. Febuxostat
9. POST HOC ANALYSIS OF ZEUS AND HERAKLES, TWO PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED TRIALS: ONSET AND PROGRESSION OF DIABETES IN KIDNEY TRANSPLANT RECIPIENTS ON CYCLOSPORINE STANDARD OR CONVERTED TO CNI-FREE OR CNI-LOW EVEROLIMUS REGIMEN: P127
10. SERUM CALCIFICATION PROPENSITY PREDICTS MORTALITY AFTER AENAL TRANSPLANTATION: P059
11. OUTCOME ON RENAL FUNCTION, EFFICACY AND SAFETY IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS AFTER CONVERSION FROM A CALCINEURIN INHIBITOR TO AN EVEROLIMUS BASED REGIMEN: A POST HOC SUBGROUP ANALYSIS OF ZEUS: V65
12. PRETRANSPLANT DSA BUT NOT COMPLEMENT FIXING HLA ANTIBODIES ARE ASSOCIATED WITH INCREASED RISK FOR ANTIBODY MEDIATED REJECTION IN KIDNEY TRANSPLANTATION: V01
13. Post Hoc Subgroup Analysis of ZEUS: Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen.: Abstract# C1917
14. Post Hoc Analysis of ZEUS and HERAKLES, Two Prospective, Open-Label, Multicenter, Randomized Trials: Onset and Progression of Diabetes in Kidney Transplant Recipients On Cyclosporine Standard or Converted to CNI-Free or CNI-Low Everolimus Regimen.: Abstract# 2921
15. Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in De Novo Renal Transplant Patients: 4 Years Follow-Up of the ZEUS Trial.: Abstract# 927 Poster Board #-Session: P92-II
16. RENAL FUNCTION IN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM TREATED DE NOVO RENAL TRANSPLANT RECIPIENTS AFTER CALCINEURIN INHIBITOR WITHDRAWAL: THE ZEUS STUDY: O-297
17. Poster Board #-Session: P113-II Efficacy and Safety of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in De Novo Renal Transplant Patients: Results of the ZEUS Trial.: Abstract# 1093
18. FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia
19. Renal Blood Oxygenation Level-dependent Imaging in Longitudinal Follow-up of Donated and Remaining Kidneys
20. Febuxostat
21. KIDNEY TRANSPLANT SURVIVAL IN PATIENTS WITH PREFORMED DONOR-SPECIFIC HLA ANTIBODIES (DSA) IN SOLID-PHASE ASSAYS - RESULTS OF A MULTICENTER STUDY FROM 18 GERMAN TRANSPLANT CENTERS
22. KIDNEY TRANSPLANT SURVIVAL IN PATIENTS WITH PREFORMED DONOR-SPECIFIC HLA ANTIBODIES IN SOLID-PHASE ASSAYS
23. Frühe Umstellung von Cyclosporin auf Everolimus nach Lebendnierentransplantation: 5 Jahresdaten der randomisierten ZEUS Studie
24. Effect of ABO incompatibility on T-cell flow cytometry cross-match results prior to living donor kidney transplantation
25. Post Hoc Subgroup Analysis of ZEUS : Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen
26. Outcome on renal function, efficacy and safety in living-donor kidney transplant recipients after conversion from a calcineurin inhibitor ton everolimus based regimen : a post hoc subgroup analysis of ZEUS
27. Post hoc analysis of ZEUS and HERAKLES, two prospective, open-label, multicenter, randomized trials : onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI-free or CNI-low everolimus regimen
28. Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in De Novo Renal Transplant Patients : 5 Years Follow-Up of the ZEUS Trial
29. A Post HOC Analysis of 2 Prospective, open-label, multicenter, randomized trials : Onset and Progression of Diabetes in Kidney Transplant Patients Receiving Everolimus or Cyclosporine. Results from Zeus and Herakles
30. 5 Years Follow-Up on renal Function - Zeus Trial : Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium regimen after Calcineurin Inhibitor Withdrawal in De Novo Renal Transplant Patients
31. Effect of ABO incompatibility on T‐cell flow cytometry cross‐match results prior to living donor kidney transplantation.
32. Renal function in Everolimus/Enterice-Coated Myophenolate Sodium treated de Novo living renal Transplant resipients after Calcineurin inhibitor Withdrawal : Subgroup analysis of the Zeus Study
33. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
34. New Onset Diabetes after Transplantation and mTOR Inhibitors : Results of the ZEUS Trial
35. Calcimimetics are promising in persistent hyperparathyroidism: the calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism
36. Active vasculitic disease demands an exact diagnosis: ANCA-negative pauci-immune renal vasculitis: histology and outcome
37. Création d’une cohorte suisse de patients lupiques : the Swiss systemic lupus erythematosus cohort study (SSCS)
38. Protocol biopsy program after renal transplantation: structure and first results
39. The Swiss Systemic lupus erythematosus Cohort Study (SSCS) – cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland
40. Post Hoc Subgroup Analysis of ZEUS: Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen.
41. Blutgruppeninkompatible Lebendnierentransplantation einer Patientin mit spenderspezifischen Antikörpern
42. Development and validation of new screening tests for nephrotoxic effects
43. Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in de Novo Renal Transplant Patients: 4 Years Follow-Up of the ZEUS Trial
44. Towards a Gold Standard for Adherence Assessment in Transplantation: High Accuracy of the Proteus Raisin System (PRS) Combined with Enteric-Coated Mycophenolate Sodium (ECMPS) in Stable Kidney Transplant Recipients
45. Échographie rénale dans la population générale suisse : premiers résultats d’une étude multicentrique
46. IMPROVED RENAL FUNCTION OF AN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM REGIMEN AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: 2 YEARS FOLLOW-UP OF THE ZEUS TRIAL
47. RENAL FUNCTION, EFFICACY AND SAFETY OF EVEROLIMUS (RAD) / ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) THERAPY AFTER CALCINEURIN INHIBITOR (CNI) WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: FINAL OUTCOMES OF THE ZEUS STUDY
48. MULTI-CENTER, OPEN-LABEL, PROSPECTIVE, RANDOMIZED, PARALLEL GROUP STUDY INVESTIGATING AN EVEROLIMUS-BASED CNI-FREE REGIMEN IN COMPARISON TO A CYCLOSPORINE-BASED STANDARD THERAPY IN DE NOVO RENAL TRANSPLANT PATIENTS (ZEUS STUDY)
49. PTH and 1.25 vitamin D response to a low-calcium diet is associated with bone mineral density in renal stone formers
50. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.